Entrar/Registro  
INICIO ENGLISH
 
Ginecología y Obstetricia de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Ginecología y Obstetricia de México >Año 2015, No. 01


Vigil-De Gracia P
Síndrome HELLP
Ginecol Obstet Mex 2015; 83 (01)

Idioma: Español
Referencias bibliográficas: 45
Paginas: 48-57
Archivo PDF: 360.87 Kb.


Texto completo




RESUMEN

El trastorno hipertensivo del embarazo es una de las complicaciones más frecuentes de éste y una de las expresiones más serias de esta enfermedad es el síndrome HELLP. Éste se distingue por el trastorno hipertensivo más las triada: hemólisis microangiopática, elevación de enzimas hepáticas y disminución del conteo de plaquetas. Las pacientes con síndrome HELLP tienen mayor riesgo de complicaciones maternas, como: hemorragia cerebral, desprendimiento de retina, hematomarotura hepática, insuficiencia renal aguda, coagulación intravascular diseminada, desprendimiento de placenta y, en algunas ocasiones, muerte materna. Se recomienda la identificación de hallazgos de síndrome HELLP en pacientes con trastorno hipertensivo del embarazo. La principal confusión clínica del síndrome HELLP es el hígado graso agudo del embarazo; sin embargo, existen parámetros que ayudan a su correcta identificación. El síndrome HELLP implica la interrupción del embarazo a corto plazo; la administración de corticoides no produce efectos favorables en la morbilidad y mortalidad materna, pero puede elevar la concentración de plaquetas, disminuir la necesidad de transfusión y acortar la estancia hospitalaria. Gran parte de la disminución de la morbilidad y mortalidad materna asociada con los trastornos hipertensivos del embarazo consiste en establecer el diagnóstico adecuado y el correcto tratamiento del síndrome HELLP.


Palabras clave: embarazo, síndrome HELLP, hipertensión.


REFERENCIAS

  1. Report of the American College of Obstetricians and Gynecologist´Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologist´Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;112:1122-1231.

  2. Federación Latinoamericana de Sociedades de Obstetricia y Ginecollogía. Módulo de Capacitación en Pre-eclampsia/ eclampsia. Guía clínica. 2012: Noviembre. [en línea]. Dirección URL: . [Consulta: junio, 2014].

  3. Witlin AG, Sibai BM. Hypertension. Clin Obstet Gynecol 1998;41:533-544.

  4. Say L, Chou D, Gemmill A, Tunçalp Ö, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health 2014;2:e323-332.

  5. Villar J, Say L, Shennan A, Lindheimer M, et al. Methodological and technical issues related to the diagnosis, screening, prevention, and treatment of preeclampsia and eclampsia. Int J Gynaecol Obstet 2004;85:S28-41.

  6. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982;142:159-167.

  7. Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynecol 1990;162:311-316.

  8. Martin JN, Blake PG, Perry KG, McCaul JF, et al. The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol 1991;164:1500-1513.

  9. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004;103:981-991.

  10. Vigil-De Gracia P. Pregnancy complicated by preeclampsiaeclampsia with HELLP syndrome. Int J Obstet Gynecol 2001;72:17-23.

  11. Vigil-De Gracia P, Tenorio-Marañón RF, Cejudo-Caranza E, Helguera-Martinez A, García-Cáceres E. Diferencias entre preeclampsia, síndrome de HELLP y eclampsia: Evaluación materna. Ginecol Obstet Mex 1996;64:337-382.

  12. Audibert F, Friedman SA, Frangieh AY, Sibai BM. Clinical utility of strict criteria for the HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol 1996;175:460-464.

  13. Abildgaard U, Heimdal K. Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obst Gynecol Rep Biol 2013;166:117-123.

  14. Buimer M, Keijser R, Jebbink JM, Wehkamp D, van Kampen, et al. Seven placental transcripts characterize HELLPsyndrome. Placenta 2008;29:444-453.

  15. Bertalan R, Patocs A, Nagy B, Derzsy Z, et al. Overrepresentation of BclI polymorphism of the glucocorticoid receptor gene in pregnant women with HELLP syndrome. Clin Chim Acta 2009;405:148-152.

  16. Cornette J, Herzog E, Buijs EAB, Duvekot JJ, et al. Microcirculation in women with severe preeclampsia and HELLP syndrome: a case-control study. BJOG 2014;121(3):363-370.

  17. Martin JN, Rinehart B, May WL, Magann EF, et al. The spectrum of severe preeclampsia: comparative analysis by HELLP syndrome classification. Am J Obstet Gynecol 1999;180:1373-1384.

  18. Vigil-De Gracia P, Ortega Paz L. Preeclampsia/eclampsia and hepatic rupture. Int J Gynecol Obstet 2012:118:186-189.

  19. Vigil-De Gracia P. Acute fatty liver and HELLP syndrome: two distinct pregnancy disorders. Int J Gynecol Obstet 2001;73:215-220.

  20. Vigil-De Gracia P, Montufar-Rueda C. Acute fatty liver of pregnancy: diagnosis, treatment, and outcome based on 35 consecutive cases. J Matern Fetal Neonatal Med 2011;24:1143-1146.

  21. Vigil-De Gracia, Ortega-Paz L. Retinal detachment in association with preeclampsia, eclampsia, and HELLP synrome. Int J Gynecol Obstet 2011:114(3):223-225.

  22. Abramovici D, Friedman SA, Mercer BM, Audibert F, et al. Neonatal outcome in severe preeclampsia at 24 to 36 weeks’ gestation: does HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? Am J Obstet Gynecol 1999;180:221-225.

  23. Amorium MMR, Santas LC, Faundes A. Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Am J Obstet Gynecol 1999;180:1283-1288.

  24. Rath W, Loos W, Kuhn W, Graeff H. The importance of early laboratory screening methods for maternal and fetal outcome in cases of HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 1990;36:43-51.

  25. Van Pampus MG, Wolf H, Ilsen A, Treffers PE. Maternal outcome following temporizing management of the HELLP syndrome. Hypertens Pregnancy 2000;19:211-220.

  26. Visser W, Wallenburg HCS. Temporising management of severe preeclampsia with and without the HELLP syndrome. Br J Obstet Gynecol 1995;102:111-117.

  27. MacKenna J, Dover NL, Brame RG. Preeclampsia associated with hemolysis, elevated liver enzymes, and low platelets: an Obstet emergency? Obstet Gynecol 1983;62:751-754.

  28. Martin JN, Thigsen BD, Rose CH, Cushman J, et al. Maternal benefit of high-dose intravenous corticosteroids therapy for HELLP. Am J Obstet Gynecol 2003;189:830-834.

  29. Vigil-De Gracia P. Addition of platelet transfusions to corticosteroids does not increase the recovery of severe HELLP syndrome. Eur J Obstet Gynecol Rep Biol 2006;128:194-198.

  30. Magann EF, Bass D, Cahuhan SP, Sullivan, Martin JN. Antepartum corticosteroids: disease stabilization in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). AM J Obstet Gynecol 1994;171:1148-1153.

  31. Magann EF, Perry KG, Meydrech EF, Harris RL, et al. Postpartum corticosteroids: accelerated recovery from the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). Am J Obstet Gynecol 1994;17:1154-1158.

  32. Vigil-De Gracia P, García-Cáceres E. Dexamethasone in the postpartum treatment of HELLP syndrome. Int J Gynaecol Obstet 1997;59:217-221.

  33. Yalcin OT, SEner T, Hassa H, Ozalp S, Okur A. Effects of postpartum corticosteroids in patients with HELLP syndrome. Int J Gynaecol Obstet 1998;61:141-148.

  34. Isler CM, Barrilleaux PS, Magann EF, Bass D, Martin JN. A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP syndrome. Am J Obstet Gynecol 2001;184:1332-1339.

  35. Fonseca JE, Mendez F, Catano C, Arias F. Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double blind, placebo controlled, randomized clinical trial. Am J Obstet Gynecol 2005;1591- 1598.

  36. -Tita A, Patrick R. Corticosteroids and HELLP. Am J Obstet Gyneco 2006;195:e7.

  37. Vigil-De Gracia P. Dexamethasone treatment and HELLP syndrome. Am J Obstet Gynecol 2006;195:e10.

  38. O´Brien J. Dexamethasone, HELLP syndrome, and study design. Am J Obstet Gynecol 2006;195:e13.

  39. Woudstra DM, Chandra S, Hofmeyr GJ, Dowswell T. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev 2010;8:CD008148.

  40. Clenney TL, Viera AJ. Corticosteroids for HELLP (haemolysis, elevated liver enzymes, low platelets) syndrome. BMJ 2004;329:270-272.

  41. Martin JN, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obstet Gynecol 2006;195:914-934.

  42. Vigil-De Gracia, Silva S, Montufar C, Carrol I, De Los Rios S. Anesthesia in pregnan women with HELLP syndrome. Int J Gynecol Obstet 2001;74:23-27.

  43. Guzmán J, Echevarría G, Kuzmanic G, Storaker M, et al. Síndrome de HELLP: Implicaciones anestésicas. Rev Chilena anestesia 2005;34.

  44. Vigil-De Gracia P. Maternal deaths due to eclampsia and HELLP syndrome. Int J Obstet Gynecol 2009;104:90-94.

  45. Martin JN, Owens MY, Keiser SD, Parrish MR, et al. Standardized Mississippi protocol treatment of 190 patients with HELLP syndrome: Slowing disease progression and preventing new major maternal morbidity. Hyperten Pregnancy 2012:31:79-90.



>Revistas >Ginecología y Obstetricia de México >Año2015, No. 01
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019